This preprint is under consideration at BMC Health Services Research. A preprint is a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
Research article
Cost-effectiveness of Anbainuo Plus Methotrexate Compared to Conventional Disease-modifying Antirheumatic Drugs for Rheumatoid Arthritis Patients in China
Jingyang Li
ZhuZhou Central Hospital, The Affiliated ZhuZhou Hospital XiangYa Medical College CSU
Corresponding Author
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Background: This study aimed to evaluate the cost-effectiveness of anbainuo (ABN) plus methotrexate (MTX) versus conventional disease-modifying antirheumatic drugs (cDMARDs) in Chinese rheumatoid arthritis (RA) patients.
Methods: Ninety RA patients who underwent ABN+MTX (assigned as ABN+MTX group (N=47)) or cDMARDs (assigned as control group (N=43)) treatment were analyzed. Disease activity was assessed at baseline (M0), 3rd month (M3), 6th month (M6) and 12th month (M12) after treatment. Drug, other medical, indirect and total costs were calculated. Then pharmacoeconomic analyses were performed with the threshold of cost-effectiveness set as 3 times of the mean gross domestic product per capita in China during the study period.
Results: Treatment response rate was similar, while disease remission and low disease activity rates were increased in ABN+MTX group compared to control group. Drug cost, other medical cost and total cost were higher in ABN+MTX group than control group, while indirect cost was similar between the two groups. Meanwhile, the quality-adjusted life years (QALY) in ABN+MTX group and control group were 0.72 and 0.48 years, respectively. The incremental cost-effectiveness ratios (ICER) of ABN+MTX group compared to control group in total patients, moderate-disease-activity patients and severe-disease-activity patients were ¥135486.7, ¥146450.4 and ¥124987.2/QALY, respectively, which were all below cost-effectiveness threshold. Further sensitivity analyses revealed that the cost-effectiveness of ABN+MTX versus cDMARDs was relative robust, while among all the indexes, ABN price and HAQ-DI score change for ABN+MTX group affected ICER most.
Conclusions: ABN+MTX treatment presents acceptable cost-effectiveness compared to cDMARDs treatment in Chinese RA patients.
Keywords
Anbainuo, Methotrexate, Conventional disease-modifying antirheumatic arthritis drugs, Rheumatoid arthritis, Cost-effectiveness
Figure 1
Figure 2
Figure 3
This is a list of supplementary files associated with this preprint. Click to download.
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Under Review
Version 1
Posted 21 Sep, 2020
No community comments so far
Reviewer #2 agreed
On 13 Nov, 2020
Review #1 received
Received 25 Oct, 2020
Reviewer #1 agreed
On 27 Sep, 2020
Editor assigned
On 21 Sep, 2020
Reviewers invited
Invitations sent on 21 Sep, 2020
Submission checks complete
On 17 Sep, 2020
Editor invited
On 15 Sep, 2020
First submitted
On 14 Aug, 2020
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Learn more about our company.
This preprint is under consideration at BMC Health Services Research. A preprint is a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
Research article
Cost-effectiveness of Anbainuo Plus Methotrexate Compared to Conventional Disease-modifying Antirheumatic Drugs for Rheumatoid Arthritis Patients in China
Jingyang Li
ZhuZhou Central Hospital, The Affiliated ZhuZhou Hospital XiangYa Medical College CSU
Corresponding Author
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Under Review
Version 1
Posted 21 Sep, 2020
No community comments so far
Reviewer #2 agreed
On 13 Nov, 2020
Review #1 received
Received 25 Oct, 2020
Reviewer #1 agreed
On 27 Sep, 2020
Editor assigned
On 21 Sep, 2020
Reviewers invited
Invitations sent on 21 Sep, 2020
Submission checks complete
On 17 Sep, 2020
Editor invited
On 15 Sep, 2020
First submitted
On 14 Aug, 2020
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Background: This study aimed to evaluate the cost-effectiveness of anbainuo (ABN) plus methotrexate (MTX) versus conventional disease-modifying antirheumatic drugs (cDMARDs) in Chinese rheumatoid arthritis (RA) patients.
Methods: Ninety RA patients who underwent ABN+MTX (assigned as ABN+MTX group (N=47)) or cDMARDs (assigned as control group (N=43)) treatment were analyzed. Disease activity was assessed at baseline (M0), 3rd month (M3), 6th month (M6) and 12th month (M12) after treatment. Drug, other medical, indirect and total costs were calculated. Then pharmacoeconomic analyses were performed with the threshold of cost-effectiveness set as 3 times of the mean gross domestic product per capita in China during the study period.
Results: Treatment response rate was similar, while disease remission and low disease activity rates were increased in ABN+MTX group compared to control group. Drug cost, other medical cost and total cost were higher in ABN+MTX group than control group, while indirect cost was similar between the two groups. Meanwhile, the quality-adjusted life years (QALY) in ABN+MTX group and control group were 0.72 and 0.48 years, respectively. The incremental cost-effectiveness ratios (ICER) of ABN+MTX group compared to control group in total patients, moderate-disease-activity patients and severe-disease-activity patients were ¥135486.7, ¥146450.4 and ¥124987.2/QALY, respectively, which were all below cost-effectiveness threshold. Further sensitivity analyses revealed that the cost-effectiveness of ABN+MTX versus cDMARDs was relative robust, while among all the indexes, ABN price and HAQ-DI score change for ABN+MTX group affected ICER most.
Conclusions: ABN+MTX treatment presents acceptable cost-effectiveness compared to cDMARDs treatment in Chinese RA patients.
Figure 1
Figure 2
Figure 3